

## Expanding the Variant Spectrum of *MED13L*-Associated Neurodevelopmental Disorder: Insights from the 100k Genomes Project

Mairena Hirschberg\*

University of Zurich, Zurich, Switzerland

\*Corresponding Author: Mairena Hirschberg, University of Zurich, Zurich, Switzerland.

Received: March 31, 2026; Published: May 06, 2026

### Abstract

**Background:** An estimated 2 - 5% of infants are born with significant congenital defects and/or go on to develop severe neurodevelopmental disorders in early childhood, with a substantial proportion attributed to underlying genetic causes. Variants in the *MED13L* gene have been linked to a syndromic neurodevelopmental disorder characterized by developmental delay, intellectual disability, and, in some cases, congenital heart defects. However, the pathogenicity of many *MED13L* variants-particularly missense changes-remains poorly understood.

**Methods:** This study analyzed clinically and genomically annotated data from the 100,000 Genomes Project (Genomics England), focusing on individuals with rare *MED13L* variants. A structured pipeline was developed to extract, filter, and interpret missense and truncating variants using the Interactive Variant Analysis (IVA) tool and associated resources. Detailed clinical phenotypes were manually cross-referenced through the Participant Explorer, and variants were classified following ACMG guidelines.

**Results:** After filtering, eight probands were identified with clinically relevant, previously unreported, *MED13L* variants: five variants of uncertain significance (VUS) and three likely pathogenic. Despite differences in classification, both VUS and likely pathogenic variants were associated with a consistent neurodevelopmental phenotype. One additional patient carried an intronic *MED13L* variant with predicted spliceogenic potential and presented with a congenital heart defect, raising the possibility of a regulatory effect on cardiac gene expression. Notably, four of the eight individuals also harbored additional pathogenic or likely pathogenic variants in other genes known to contribute to neurodevelopmental phenotypes, illustrating potential genetic heterogeneity. The study also identified a disproportionately high rate of VUS among individuals of non-European ancestry, highlighting challenges in variant interpretation due to underrepresentation in population databases.

**Conclusion:** This work emphasizes the value of large-scale genomic datasets in refining variant classification and improving diagnostic accuracy. It highlights the complexity of interpreting *MED13L* variants, the importance of considering genetic heterogeneity, and the need for increased diversity in genomic reference databases. Findings underscore the necessity of trio sequencing and functional studies to reclassify VUS and advance understanding of *MED13L*-associated syndromes.

**Keywords:** *MED13L*; Variants of Uncertain Significance; Neurodevelopmental Conditions; Genomic Analysis; Patient Management; 100k Genomes Project

### Introduction

Approximately 2 - 5% of infants are born with significant congenital defects, and/or they experience severe neurodevelopmental abnormalities during infancy. While various factors, such as gestational infection and maternal alcohol use, can result in neurodevelopmental abnormalities, harmful genetic variation in developmentally crucial genes plays a significant role [1].

One notable example of those genes is the Mediator complex, an emerging set of genes linked to neurodevelopmental disorders.

The Mediator complex is an essential component of the transcription machinery in eukaryotic cells. It acts as a bridge connecting transcription factors, which bind to DNA at specific sequences, with RNA polymerase II (Pol II), the enzyme responsible for synthesizing mRNA from a DNA template [2]. Among the genes of the mediator complex, *MED13L* is one of the most frequently mutated genes [3] causing intellectual disability, speech impairment, hypotonia, distinctive facial gestalt and variable other anomalies such as congenital heart defects and epilepsy [4].

Muncke, *et al.* (2003) were the first to implicate *MED13L* (formerly *PROSIT240*) in human disease, demonstrating that disruptions of this gene were associated with congenital heart defects, particularly transposition of the great arteries, as well as intellectual disability. In their cohort, six intronic variants and three missense variants were identified, suggesting early on that both coding and non-coding alterations might contribute to disease pathogenesis [5]. Subsequently, through deep sequencing approaches, Najmabadi, *et al.* (2011) identified 50 novel genes associated with recessive cognitive disorders, including *MED13L*. In that study, a homozygous missense *MED13L* variant was observed in two affected siblings, thereby broadening the phenotypic spectrum of *MED13L*-related disorders beyond congenital heart defects to encompass cognitive impairment [6].

Further work underscored the importance of *MED13L* gene dosage, demonstrating that both haploinsufficiency and overexpression can result in congenital heart defects and intellectual disability, highlighting the necessity of tightly regulated *MED13L* expression during development [7]. The haploinsufficiency model was reinforced by the identification of additional individuals harboring pathogenic *MED13L* variants [8].

Functional investigations provided mechanistic insight into the cellular consequences of *MED13L* insufficiency, revealing a pivotal role in neural crest cell development with downstream effects on organogenesis and neurodevelopment [9]. In parallel, *in silico* structural modeling of a missense variant identified in a patient with intellectual disability predicted disruption of  $\alpha$ -helical stability and secondary structure, consistent with a deleterious molecular impact [4].

Although multiple missense variants in *MED13L* have since been reported [5,6], many remain classified as variants of uncertain significance (VUS), and their precise contribution to disease pathogenesis continues to be actively debated [4].

### Aims and Objectives of the Study

The overarching aim of this study is to provide a comprehensive analysis of missense variants (including (likely) benign, variants of uncertain significance and (likely) pathogenic variants) within *MED13L*, and to explore the phenotypic spectrum associated with its variants. This study is leveraging data from the 100,000 Genomes Project - Rare Disease Subgroup, one of the most expansive and representative datasets currently available for rare disease research.


A key strength of this study is the use of the 100,000 Genomes Project dataset, which provides a large and demographically diverse cohort, enabling robust and generalizable analyses beyond the constraints of small, clinically ascertained cohorts.

## Data and Methods Section

### Advancing our understanding of *MED13L* through the genomics England dataset

This study was based on data from the Genomics England dataset, providing insight into the genetic landscape of *MED13L*-associated syndrome within a large and representative cohort. Unlike traditional datasets, which are often limited to a few hundred individuals and subject to referral bias, the Genomics England (GE) dataset comprised a broader and more diverse population. This breadth enhanced the generalizability of the findings and reduced biases commonly associated with smaller, clinically ascertained cohorts. The comprehensive nature of the GE data allowed for a more accurate assessment of *MED13L*-associated phenotypes, contributing to a deeper understanding of the disorder’s clinical variability and genetic architecture.

Across all Genomics England Projects, 64,52% of participants were white British, a further 9,03% were from “Any other white background” (Figure 1). Of the 73,605 participants, 52.19% were female and 47.79% were male (Figure 2). Participants were born between 1925 and 2020, representing a broad age range (Figure 3). Within the rare disease group, clinical records indicated that 40,481 individuals had a documented disease diagnosis (Figure 4). A subset of 17,150 participants was identified as having a neurodevelopmental condition. The most common diagnoses within this group included developmental disorder of scholastic skills and unspecified disorder of psychological development (Figure 5).



**Figure 1:** Demographic information across all Genomics England Projects: Self defined ethnicity [25].

Chromosomal Sex (group)	% of Total Participants along Chromosomal S..	Participants
XX	52.19%	38,824
XY	47.78%	35,540
Other	0.03%	25

Figure 2: Demographic information across all Genomics England Projects: Chromosomal Sex [25].




Figure 3: A Demographic information across all Genomics England Projects: Year of birth (taken from Genomics England Public Data Browser) [25].



Figure 4: Types of rare diseases in the 100k Genomes rare disease group (taken from Genomics England Public Data Browser) [26].

ICD-10 Categories Table		
ICD-10 Code	Term	Record Count
F80.2	Mixed receptive-expressive language disorder	36
F80.3	Acquired aphasia with epilepsy [Landau-Kleffner]	19
F80.8	Other developmental disorders of speech and language	89
F80.9	Developmental disorder of speech and language, unspecified	1891
F81.0	Specific reading disorder	52
F81.1	Specific spelling disorder	<5
F81.3	Mixed disorder of scholastic skills	36
F81.8	Other developmental disorders of scholastic skills	76
F81.9	Developmental disorder of scholastic skills, unspecified	4819
F82	Specific developmental disorder of motor function	805
F83	Mixed specific developmental disorders	827
F84.0	Autistic disorder	3085
F84.1	Atypical autism	178
F84.2	Rett's syndrome	61
F84.3	Other childhood disintegrative disorder	9
F84.4	Overactive disorder associated with mental retardation and stereotyped movements	5
F84.5	Asperger's syndrome	246
F84.8	Other pervasive developmental disorders	41
F84.9	Pervasive developmental disorder, unspecified	219
F88	Other disorders of psychological development	284
F89	Unspecified disorder of psychological development	4194

Figure 5: Overview of disorders of psychological development (F80-F89) in the 100k Genomes rare disease cohort [27].

All genomic and clinical data had undergone processing through the Genomics England Interpretation Pipeline prior to analysis. Only genomes that passed stringent quality control (QC) criteria, including contamination assessment, concordance between genetic and reported data, and adequate sequencing coverage, were included. This ensured the integrity and reliability of the data analysed [10].

### Variant filtering and annotation

To investigate the clinical significance of *MED13L* missense variants, a structured bioinformatics pipeline was developed and applied to data from 100k Genomes Project Interactive Variant Analyser GrCh38 and GrCh37 Germline Programme. A minor allele frequency (MAF) threshold of <0.01 was applied to variants in *MED13L* to exclude common variants. The variants were then filtered by variant type (INDEL or SNV) and consequence type (missense or truncation). Missense variants were selected for focused analysis. Based on gnomAD allele counts and frequencies were determined. The localization of variants within gene-specific hotspots was considered, as well as previously reported variants in the literature and ClinVar. For this study, variants not previously reported were prioritized.

### Participant and phenotype selection

Probands presenting with neurodevelopmental or neurodevelopmental and or neurodevelopmental and anatomical cardiac features were retained, while those with non-anatomical cardiac anomalies were excluded. Relevant clinical data-including *de novo* status, ethnicity, and family structure-were extracted using the Participant Explorer. Variants observed in more than 10 individuals-or in more than 50 individuals across the full cohort-were excluded to minimize the possibility of technical artifacts.


### Variant classification

Variants were classified according to ACMG/AMP guidelines. The following criteria were considered: phenotype consistency (PP4), *de novo* origin (PS2), absence from population databases (PM2), and *in silico* predictions (PP3), based on Ensembl Variant Effect Predictor (VEP), incorporating CADD, SIFT, and AlphaMissense scores.

**Characterization of probands**

Detailed clinical profiles were compiled for all probands carrying filtered *MED13L* variants. Features were compared between those with likely pathogenic variants and those with variants of uncertain significance. A comprehensive literature review was conducted to confirm the novelty of each variant.

Through this approach, nine probands with rare *MED13L* variants were identified and characterized, contributing to the broader understanding of the gene’s role in neurodevelopmental disorders (See figure 6).



**Figure 6:** Variant filtering steps and number of variants after each filtering step.

**Results**

**Primary variant filtering - Overview of the spectrum of *MED13L* missense and truncating variants in the genomics England rare disease cohort**

A total of 438 missense *MED13L* variants were identified in the 100k Genomes Project Interactive Variant Analyser GrCh38 Germline Programme. Of these, 91 variants were absent from gnomAD, indicating that they are previously unreported.

Among the 1,530 probands carrying one of the 438 missense variants, ten individuals met the initial criteria for a neurodevelopmental phenotype. Upon detailed phenotypic review, three probands were excluded due to the absence of a neurodevelopmental component. An additional case was excluded because the corresponding MANE Select transcript classified the variant as intronic rather than missense.

After applying these criteria, seven individuals remained with phenotypes consistent with *MED13L*-associated neurodevelopmental disorder. Of these, three probands carried variants classified as likely pathogenic, corresponding to a prevalence of 0.004% within the 63,349 participants of the IVA rare disease cohort. Four probands harbored VUS, corresponding to a prevalence of 0.006% in the same cohort.

Among the 1,530 probands carrying missense variants, the four VUS cases represent 0.261% of missense carriers. Within the final phenotypically consistent subgroup (n = 7), VUS accounted for 57.1% of cases (4/7), while likely pathogenic variants accounted for 42.9% (3/7).

In contrast, 268 probands within the IVA rare disease cohort carried truncating variants in *MED13L*, which are generally considered consistent with haploinsufficiency and thus more likely to be pathogenic. These filtering steps are illustrated in figure 6 and detailed in table 1.

Type of variants	Absolute numbers	Number of participants	Percentage of variants
Total number of variants affecting <i>MED13L</i> (all types of coding and non-coding variants) (from 100k Genomes Project GRCh38 Germline programme - rare disease programme, March 2025)	66937 variants observed in the IVA rare disease programme	63349 participants	100%
Number of variants with MAF <0.01 (less than 1%) (from GnomAD) (from 100k Genomes Project GRCh38 Germline programme - rare disease programme)	65857 variants		98.387%
Number of variants that are truncating (frame shift, stop gained, splice acceptor and splice donor variants, Indel (less 50bp) and SNV) (from 100k Genomes Project IVA rare disease GRCh38 cohort) - without applying MAF	57 variants	268 probands	0.085%
Number of missense/inframe variants (from 100k Genomes Project GRCh38 Germline programme - rare disease programme)	438 variants (when filtering for MAF <0.01, it is 438 variants as well)	1530 probands	0.654%
Number of variants left after including variants unreported in GnomAD (from GnomAD)	91 variants	--	0.136%
Number of variants after excluding people who did not fit phenotype (with no neurodevelopmental feature) or families where several members had same <i>MED13L</i> variant but different phenotypes (from 100k Genomes Project GRCh38 Germline programme - rare disease programme)	7 variants	7 probands	0.01%
Number of VUS (from 100k Genomes Project GRCh38 Germline programme - rare disease programme)	3 variants	3 probands	0.01%

**Table 1:** Overview of numbers after filtering steps of *MED13L* gene variants from the 100k Genomes Project GRCh38 Germline Programme (Rare Disease Programme).

### Exonic missense mutations in the *MED13L* gene

In both data from GRCh38 and GRCh37 together, I identified eight heterozygous missense variants in *MED13L* in eight unrelated patients (P1-P8), all absent from both GnomAD and ClinVar databases (as of January 21, 2025). In cases where parental data were available, the variants were found to have occurred *de novo* (patients P5, P6, and P7). Consanguinity was documented in patients 1 and 6.

### Variants were distributed across the gene

c.250T>C p.(Trp84Arg), c.2432A>G p.(Asp811Gly), c.4745C>A p.(Ser1582Tyr), c.1466A>G p.(His489Arg), c.1688C>A, p.PRO563GLN, c.2614>A p.(Glu872Lys), c. 3688-3693 TC/- (GrCh37) and c.6077 G/A p.(Gly1957Val) (GrCh37).

The c.1466A>G p.(His489Arg), c.1688C>A, p.PRO563GLN and c.1688C>A p.(Glu872Lys) substitutions were predicted to be deleterious by SIFT (score = 0) and had CADD scores ranging from 22.4 to 27.6.

Patient 4 carried an intronic *MED13L* variant (NM\_015335.5:c.5589-20C>T; chr12:115975333G>A, GRCh38), which does not result in an amino acid substitution in the MANE Select transcript.

Patients 3, 5, 6 and harbored additional rare variants or chromosomal abnormalities in additional genes (*RPSAP62*, *IQSEQ2*, *COQ4*, and *TRUB2*), potentially contributing to their phenotypes.

### Description of patients with VUS and pathogenic variants

Due to the limited sample size, the findings of this study should not be considered representative of broader populations.

### Demographic and genetic findings

Among the three patients classified with variants of uncertain significance (VUS), two were of Asian or Asian British (Pakistani and Indian) or mixed (White and Asian) descent, while one patient was of White British ancestry. In contrast, among the three cases classified as likely pathogenic, two were of White British descent, and one patient was of Asian British (Indian) descent.

Consanguinity was documented in two cases: one patient with a VUS who had Indian parents, and one patient with a likely pathogenic variant who had Pakistani parents.

All patients with VUS were female. Among those with likely pathogenic variants, two were female, and one was male. All individuals in this cohort were born in the early 2000s.

In two out of three VUS cases, no definitive causative variant could be identified. In all VUS cases, the VUS classification was attributable to undetermined inheritance patterns, as only one parental genome was available for sequencing, precluding confirmation of *de novo* status (Table 2).

### Patient classification

The following patient subgroups were identified:

- a) Patients with a VUS in *MED13L* who remain molecularly undiagnosed: These individuals harbored *MED13L* VUS without additional pathogenic findings, leaving them without a definitive molecular diagnosis (Patients 1 and 2 and 8 and 9).

---

<sup>1</sup>The following results refer to various databases as of 18th March 2026.

Patient number and variant type	Sex	Year of Birth	Ethnicity	Cardiac manifestations	ID	Other manifestations	NGS analysis carried out	Mutation
Patient 1 -VUS	F	2010	Asian (Pakistani)	No	Yes	No	Inheritance undetermined, only one parent sequenced	p.TR84ARG
Patient 2 -VUS	F	2012	White (British)	No	Yes	No	Inheritance undetermined, only one parent sequenced	p.ASP811GLY
Patient 3 VUS	F	2004	Asian (Indian)	No	Yes	No	Inheritance undetermined, only one parent sequenced	p.SER1582TYR
Patient 4 - VUS	M	1998	Mixed: White and Asian	Yes, other congenital malformations of aorta Q25.4	yes	no	Inheritance undetermined, only one parent sequenced	Intronic variant
Patient 5 Likely pathogenic	F	2013	White (British)	No	Yes	No	<i>De novo</i>	p.HIS489ARG
Patient 6 - Pathogenic	M	2015	Asian or Asian British (Indian)	Bradycardia	Yes	No	<i>De novo</i>	p.PRO563GLN
Patient 7 - likely pathogenic	F	2012	British (White)		Yes	No	<i>De novo</i>	p.GLU872LYS
Patient 8 (from GrCh37) - Variant of Uncertain Significance	F	2010	British (White)	No	Yes	No	Inheritance undetermined, only one parent sequenced	(Deletion)
Patient 9 (from GrCh37) - Variant of Uncertain Significance	F	2009	British (White)	No	Yes	No	Inheritance undetermined, parents not sequenced	p.GLY1957VAL

**Table 2:** Overview of characteristics of patients relating to demography, phenotype and genotype.

- b) Patients with a VUS in *MED13L* but with an established molecular diagnosis (pathogenic variant in another gene alongside the VUS): A likely pathogenic variant was identified in another gene, which is consistent with the proband’s clinical features. As the molecular diagnosis accounts for the phenotype, the impact of the VUS in *MED13L* on the clinical picture is uncertain (Patient 3).
- c) Patients with pathogenic variants in *MED13L* and/or additional genes: These patients exhibited pathogenic variants in *MED13L* alongside additional pathogenic findings contributing to their overall disease presentation (Patients 5, 6 and 7) (See table 3 and 4).

Patient Number	Variant classification	Additional Comments	Patient type	Implication	Recommendations for a diagnostic lab
Patient 1	VUS in <i>MED13L</i> , no other variants		VUS		Consider further action: Additional tests/investigations (trio sequencing) could re-classify the VUS as likely pathogenic
Patient 2	VUS in <i>MED13L</i> , no other variants		VUS		Consider further action: Additional tests/investigations (trio sequencing) could re-classify the VUS as likely pathogenic
Patient 3	VUS in <i>MED13L</i> and <i>asxl3</i> (pathogenic variant)		VUS and pathogenic variant-VUS		Consider further action: Additional tests/investigations (trio sequencing) could re-classify the VUS as likely path.
Patient 4	VUS in <i>MED13L</i> , no other variants	Heart: other congenital malformations of aorta (Q25.4), cardiac phenotype	VUS		
Patient 5	Likely pathogenic in <i>MED13L</i> ,  Also variants in <i>RPSAP62</i> , <i>IQSEQ2</i> : AC245102 (accession number)	Mild phenotype	Pathogenic and Likely Pathogenic	2 diseases causing variants at the same time	Report to Genomics England about likely pathogenic variant newly found by the present study, to pass on information to the clinician
Patient 6	Primary coenzyme q10 deficiency, and likely pathogenic in VUS, variants in <i>COQ4</i> and <i>TRUB2</i>	Bradycardia	Pathogenic and Likely Pathogenic	2 diseases causing variants at the same time	Report to Genomics England about likely pathogenic variant newly found by the present study, to pass on information to the clinician
Patient 7	Pathogenic in <i>MED13L</i> , chromosomal abnormality		Pathogenic	Replication (as already reported by Genomics England)	Consider further action: Additional tests/investigations (trio sequencing) could re-classify the VUS as likely path.
Patient 8	VUS in <i>MED13L</i> (confirmed by Genomics England), no other variants		VUS	Replication (as already reported by Genomics England)	Consider further action: Additional tests/investigations (trio sequencing) could re-classify the VUS as likely path.
Patient 9	VUS in <i>MED13L</i> , no other variants		VUS	Replication (as already reported by Genomics England)	Consider further action: Additional tests/investigations (trio sequencing) could re-classify the VUS as likely path.

**Table 3:** Patient types identified by the present study and their implications as well as recommendations.

Patient	C.nomenclature/ p.nomenclature	Absent from database (reported in GnomAD)	Absent from database (reported in ClinVar on 21 <sup>st</sup> Jan 2025)	NGS analysis carried out	Computational evidence (in silico predictions CADD, SIFT, Polyphen, AlphaMissense)	SIFT	Polyphen	CADD	Alphamissense (with score)	Published in the literature	Final classification
Patient 1	c.250T>C/ p.TRP84ARG	No	No	Duo (absent in mother or father)	3 pathogenic lines of evidence	Deleterious (0)	0 (unknown)	25/4.339121	Likely pathogenic (0.9988)	No	VUS
Patient 2	c.2432A>G/ p.ASP811GLY	No	No	Duo (absent in mother or father)	2 pathogenic lines of evidence	Deleterious (0)	Unknown (0)	29.2	0.4252778 (ambiguous)	No	VUS
Patient 3	c.4745C>A/p. SER1582TYR	No	No	Duo (absent in mother or father)	2 pathogenic lines of evidence	Deleterious(0)	Unknown (0)	23.4	0.1857(likely benign)	No	VUS (leans towards benign, as patient has other disease causing mutation (ASXL3))
Patient 4	Intronic variant	No	No	Duo (absent in mother or father)	2 pathogenic lines of evidence	Intronic isoform	Max- EntScan- diff  -0.234	MaxEntScan- Alt  8.680		No	VUS
						Mis- sense isoform  0.04 (tolerated low confidence)	0.001	0.139432 (RawScore), 1.823 (PHRED score) <sup>1</sup>  -benign	Not available		
Patient 5	c.1466A>G/p. HIS489ARG	No	No	Trio	2 pathogenic lines of evidence	Deleterious (0)	Unknown (0)	22.2	Ambiguous (0.4852)	No	Likely Pathogenic
Patient 6	c.1688C>A/p. p.PRO563GLN	No	No	Trio	2 pathogenic lines of evidence	Deleterious (0)	Unknown (0)	26.5	Ambiguous (0.4309)	No	Likely Pathogenic

1 <https://cadd.gs.washington.edu/snv>

Pa-tient 7	c.2614G>A/ p.GLU872LYS	No	No	Trio- on GEL <i>de novo</i> list	3 pathogenic lines of evidence	Deleterious (0)	0	27.6	Likely pathogenic (0.9851)	No	Likely Pathogenic (classified likely path. in GEL)
Pa-tient 8	c.3481_3486/p.Thr1161_Cys1162	No	No	Duo	Not available as inframe deletion					No	VUS
Pa-tient 9	c.5870G>C/ p.Gly1957Val	No	No	Singleton	2 pathogenic lines of evidence	Benign (0.06)	Pa-thogenic (0.999)	Pathogenic (26.2)	Benign (0.1789)	No	VUS

**Table 4:** Variant classification based on criteria by the American College of Medical Genetics and Genomics [28].

#### Intronic mutation in the *MED13L* gene

In the MANE Select transcript (NM\_015335.5), the variant was located within the intronic region, 20 nucleotides upstream of the exon-intron boundary (Figure 7). Although it does not alter the coding sequence, this position lies within a region that may influence pre-mRNA splicing. To evaluate its potential spliceogenic effect, maximum entropy (MaxEntScan) scores were calculated for both the reference and alternate alleles. Comparison of the reference (ref) and alternate (alt) scores, as well as the differential (ref – alt), suggested an enhancement of splice site strength in the presence of the variant. Specifically, the alternate allele yielded a score exceeding 8.5 and a negative differential score of –0.234, consistent with the potential creation or strengthening of a cryptic splice site [11].

Initially, the variant was annotated as a missense alteration in an alternative transcript (ENST00000552447), resulting in a PRO→SER amino acid substitution.


However, subsequent attempts to confirm the missense annotation using Ensembl Variant Effect Predictor (VEP) were unsuccessful. Neither genomic coordinate search (12:115975333) nor transcript-based queries returned supporting evidence for the existence of this isoform. The transcript has since been deprecated and archived by UCSC, and no longer appears in current annotations under the GRCh38/hg38 assembly (See figure 7). As a result, the variant is no longer categorized as a missense variant in either UCSC or Ensembl VEP databases, leading to reclassification of the variant as intronic.

As the variant is at present classified as intronic, it was considered out of scope for this project.

This patient also presented with congenital heart malformations, adding clinical complexity to variant interpretation.

#### Phenotype of patients with VUS and pathogenic variants

All eight probands presented with intellectual disability and severe speech delay, suggesting a consistent neurodevelopmental phenotype associated with *MED13L* missense variants. Seizures or abnormal EEG findings were reported in six out of eight individuals (75%), indicating a high prevalence of neurological involvement. Hypotonia was observed in three cases (37.5%), while autistic features were noted in three individuals (37.5%).



**Figure 7:** Variants at the position 12:115975333 G/A of the *MED13L* gene above in the UCSC Genome Browser on Human (GRCh38/hg38) and below in the UCSC Genome Browser on Human (GRCh37/hg37) with the archived missense variant ENST0000052447 (<https://genome.ucsc.edu/>).

Facial dysmorphism was documented in three probands (37.5%), with specific findings including low-set ears and a bulbous nasal tip, each reported in two (25%) and one participants respectively. Abnormal brain MRI and abnormal EEG findings were each noted in one case (12.5%).

Growth abnormalities were present in two probands (33.3%). Microcephaly was observed in three cases (37.5%), with additional postnatal weight anomalies recorded-one individual exhibited postnatal underweight and another postnatal overweight. A complex congenital heart defect was also reported in one individual, who carried an intronic variant predicted to affect splicing and was not included among the eight individuals with missense variants (See table 5).

Clinical Feature	My Study (n = 9)	Study by Smol., et al. [12]	Previous Studies [12]
DD/ID	8/8 (100%)	100% (36/36)	100% (30/30)
Motor delay	8/8 (100%)	100% (36/36)	100% (19/19)
Speech delay	8/8 (100%)	100% (36/36)	100% (30/30)
Hypotonic open-mouth	Not measured by Genomics England	78% (25/32)	78% (14/18)
Hypotonia	3/8 (37.5%)	77% (26/34)	62% (18/29)
Ataxia	0/8 (0.00%)	34% (11/32)	32% (9/28)
Behavioral troubles	Not measured by Genomics England	31% (10/32)	32% (6/19)
CHD	1 (intronic variant)	11% (3/27)	24% (6/25)

Autistic features	3/8 (37.5%)	34% (10/29)	21% (6/29)
Seizures	6/8 (75%)	17% (6/35)	14% (4/28)
Abnormal EEG	1/8 (12.5%)		
Abnormal growth parameters	2/8 (25%)		
Abnormal MRI	1/8 (12.5%)		
Facial features			
Facial dysmorphism	3/6 (37.5%)		
Bulbous nasal tip	Bulbous nose 1/8 (12.5%)	82% (27/33)	74% (17/23)
Upslanting palpebral fissures	0/8 (0.00%)	34% (11/32)	62% (15/23)
Bitemporal narrowing	0/8 (0.00%)		
Broad/prominent forehead	0/8 (0.00%)		
Cupid-bow upper lip		58% (18/31)	
Deep philtrum		58% (18/31)	
Depressed/flat nasal bridge	0/8 (0.00%)		
Horizontal eyebrows	0/8 (0.00%)		
Low set ears	2/8 (25%)		
Macrocephaly	0/8 (0.00%)		
Macroglossia	0/8 (0.00%)		
Microcephaly	3/8 (37.5%)		
Thin vermilion border		52% (17/33)	
Abnormal chin	0/8 (0.00%)		
Postnatal overweight	1/8 (12.5%)		
Postnatal underweight	1/8 (12.5%)		
Aggressive behavior	0/8 (0.00%)		

**Table 5:** Frequency of key clinical characteristics in the reported patients, patients in the study by Smol., et al. and patients from previous studies [12]. The aforementioned features of the probands in my study are based on the patient descriptions found in the Participant Explorer; features that are not documented are neither considered present nor absent.

These findings underscore the variable expressivity of *MED13L*-associated phenotypes, with a core neurodevelopmental presentation often accompanied by seizure activity, hypotonia, dysmorphic features, and, in some cases, structural brain or cardiac anomalies.

### Impact of filtering strategy on variant counts

The observed distribution of retained variants was strongly influenced by the way genomic data are processed and represented within the Genomics England Interactive Variant Analyser (IVA) platform (Figure 6).

Application of a minor allele frequency (MAF) threshold of <0.01 resulted in only a modest reduction in variant counts. This unexpected finding can be attributed to IVA's treatment of population frequency data: variants absent from gnomAD are assigned an alternate allele frequency of zero. Consequently, such variants are retained under a <0.01 threshold despite lacking independent population frequency

evidence. This platform-specific annotation approach explains the limited impact of MAF filtering in the present dataset (Personal Communication, Genomics England Service Desk, 16 December 2024).

In contrast, consequence-based filtering produced the most pronounced reduction in candidate variants. Consistent with Genomics England's default settings, synonymous variants were excluded, and only missense (SO:0001583) and feature truncating (SO:0001906) variants were retained. Because these variant classes are predicted to alter protein structure or function, this step substantially enriched the dataset for potentially pathogenic alterations.

Additional refinement was achieved through phenotype-driven filtering. Restricting analysis to probands presenting with neurodevelopmental phenotypes-with or without associated structural cardiac anomalies-aligned the variant set with the established clinical spectrum of *MED13L*-related disorders. Isolated cardiac anomalies were not considered sufficient for inclusion in the absence of neurodevelopmental features. In familial cases, only those with concordant phenotypes among affected individuals were retained, thereby reducing the risk of misattributing variants to unrelated clinical presentations.

Together, these filtering steps clarify how analytical design choices and platform-specific assumptions shaped the final variant counts observed in this study.

### Discussion

In this study, I report eight individuals harboring non-recurrent variants in the neurodevelopmental disorder-associated gene *MED13L*, including three classified as likely pathogenic and five as variants of uncertain significance (VUS), thereby extending the known spectrum of missense variants in this gene. One individual with an intronic variant in *MED13L* and a heart phenotype was found.

In line with previous research, a clearly delineated phenotype was found, as all eight probands suffered from intellectual disability, motor delay and speech delay.

As confirmed in the literature there was a high number of patients with epilepsy (6 out of 8 patients) in patients carrying *MED13L* missense variants [4,12].

Importantly, no significant phenotypic differences were observed between individuals with VUS and those carrying pathogenic *MED13L* variants. This observation aligns with prior reports suggesting considerable phenotypic overlap across the variant spectrum in *MED13L*-related disorders [4,7,8,13].

### Clinical implications of findings

Genetic heterogeneity-defined as pathogenic variants in different genes or alleles producing similar clinical phenotypes-emerged as a recurring feature within this cohort. In four of the eight probands, additional pathogenic or likely pathogenic variants were identified in genes distinct from *MED13L*, including *ASXL3*, *IQSEC2*, and *COQ4*. These genes are independently associated with neurodevelopmental disorders that may clinically overlap with *MED13L*-related syndromes. The presence of multiple pathogenic variants in individual probands raises the possibility of multilocus contributions to the observed phenotypes.

To date, most studies focused specifically on *MED13L* syndrome have not reported comparable levels of genetic heterogeneity [7,8,13]. A notable exception is the study by Mullegama., *et al.* which described a patient harboring pathogenic variants in both *DEAF1* and *MED13L*. Following *in vitro* functional analyses and comprehensive phenotypic evaluation, the authors concluded that the clinical presentation was most consistent with *MED13L* haploinsufficiency syndrome [14].

The discrepancy between prior reports and the present findings may reflect differences in study design and cohort ascertainment. The Genomics England dataset, from which several participants in this study were drawn, recruits broadly across rare diseases rather

than exclusively targeting neurodevelopmental phenotypes. Moreover, all participants undergo whole-genome sequencing, rather than phenotype-driven targeted gene panel sequencing, thereby enabling the detection of pathogenic variants beyond those initially suspected based on clinical presentation. Such an approach may increase the likelihood of detecting co-occurring pathogenic variants and capturing a more genetically heterogeneous population.

More broadly, emerging evidence in neurodevelopmental disorders supports the concept of cumulative genetic burden. A recent case study described a patient carrying heterozygous variants in *HDAC8* and genes within the FA/BRCA pathway, suggesting a potential combined effect on disease expression [15]. Similarly, oligogenic models are increasingly considered in autism spectrum disorder, where multiple rare variants may contribute additively or interactively to phenotypic manifestation [16,17].

### Case studies of genetic heterogeneity

Patient 3 was diagnosed with Bainbridge-Ropers syndrome (#OMIM 615485) due to a pathogenic nonsense variant in *ASXL3* (chromosome 18: position: 33746183, c.6335 T>A; p.Leu2112Ter), causing a stop mutation alongside a VUS in *MED13L*. Bainbridge-Ropers syndrome (BRPS) presents with clinical features overlapping *MED13L* syndrome, including severe intellectual disability, delayed psychomotor development, hypotonia, feeding difficulties, growth impairment, and dysmorphic facial characteristics [18].

Patient 5, a female proband, harbored multiple pathogenic or likely pathogenic variants, including alterations in *IQSEC2* and *MED13L*. Genomic analysis identified a TG/T deletion at chromosomal position X:53320894 within *IQSEC2* (UniProt accession AC245102) [19]. This deletion results in a frameshift predicted to produce a truncated or functionally compromised protein and was classified as pathogenic by Genomics England.


Pathogenic variants in *IQSEC2* are typically associated with severe intellectual disability, hypotonia, strabismus, stereotypic behaviors, autism spectrum disorder, postnatal microcephaly, and epilepsy [20].

As *IQSEC2*-related disorders follow an X-linked dominant inheritance pattern [20], affected females are frequently less severely impacted than males. This sex difference is attributed to X-chromosome inactivation (XCI), whereby heterozygous females exhibit mosaic expression of mutant and wild-type alleles. Depending on the degree of XCI skewing, this mosaicism can lead to a milder or more variable phenotype. Consistent with this mechanism, Kalscheuer, *et al.* (2016) reported attenuated clinical manifestations in female carriers within affected pedigrees [21].

The proband exhibited several features consistent with *IQSEC2*-related neurodevelopmental disorder, particularly intellectual disability and hypotonia. However, in contrast to the classical presentation, no recurrent or unprovoked seizures were reported; seizure activity was limited to febrile convulsions. Given that epilepsy is a common and often prominent feature of *IQSEC2*-associated disease, the absence of epilepsy in this patient suggests a comparatively attenuated phenotypic presentation, in line with the literature on female patients. However, the relative contribution of each gene to the overall clinical presentation remains uncertain.

Notably, *RPSAP62*, also identified in this proband, has no established disease association in OMIM and is likely an incidental finding.

In addition to a likely pathogenic *MED13L* mutation, patient 6 harbored a pathogenic variant in *COQ4* as well as a variant in *TRUB2*. While *TRUB2* is not known to be associated with any disease and likely incidental, *COQ4* is implicated in pathogenicity. Notably, *TRUB2* and *COQ4* are located in close genomic proximity. Complex structural variations such as a deletion-insertion-duplication event could potentially encompass these two loci, representing a larger genomic rearrangement (See figure 8).



**Figure 8:** The *TRUB2* gene (left) and the *COQ4* gene (right) are located in close proximity, as visualized using the UCSC Genome Browser for the human genome (GRCh38/hg38) (<https://genome.ucsc.edu/>).

Mutations in *COQ4* have been linked to primary coenzyme Q10 deficiency, a condition with a clinically heterogeneous presentation. While most cases exhibit variable neurological symptoms, Brea-Calvo, *et al.* reported a patient with *COQ4*-related disease who exhibited a progressive course of neurological deterioration [22]. Given the broad neurodevelopmental phenotype observed in this patient, it is evident that the proband presents with a dual diagnosis of *MED13L* syndrome and primary coenzyme Q10 deficiency, highlighting the complexity of the underlying genetic etiology.

**Patient 7** - This patient was initially diagnosed by Genomics England with a likely pathogenic variant in the *MED13L* gene, a finding that was subsequently confirmed in the present study. In addition to this pathogenic variant, the patient has been assigned a diagnosis of chromosomal abnormality, classified under the ICD-10 code for chromosomal disorders. However, the clinical significance of this chromosomal abnormality remains uncertain, and it is unclear whether it contributes to the patient's neurodevelopmental phenotype.

The present result corroborates previous findings from Genomics England, thereby replicating and reinforcing established genotype-phenotype associations.

### Intronic variants

Patient 4 distinguished himself in this cohort by exhibiting a unique combination of features. Specifically, this individual presented with a primary intronic isoform in *MED13L* (See figure 7) and was the only patient in the study to show congenital malformations of the aorta (ICD-10 Q25.4) alongside neurodevelopmental symptoms. These findings fulfill the criteria for a cardiac phenotype.

The variant, although located in a non-coding intronic region, resides within a domain implicated in splicing regulation and displays clear spliceogenic potential. Supporting this, the variant demonstrated a negative differential entropy score (-0.234) and a high alternate score (>8.5), consistent with the creation of a *de novo* or cryptic splice site and suggestive of aberrant splicing [11]. Such regulatory mutations, even when occurring outside canonical coding sequences, may significantly influence isoform expression and, consequently, organ development-including the heart.

It is also important to note that this particular *MED13L* variant is not listed in current public variant databases, and its expression profile in cardiac tissue remains unconfirmed.

This is in line with the literature, which has attributed such phenotypic variability to reduced penetrance of cardiac defects in *MED13L* syndrome [13]. Adegbola, *et al.* (2015) were the first to describe a cohort of eight individuals with *MED13L* mutations who, while demonstrating syndromic neurodevelopmental features, lacked complex congenital heart defects. Their findings, consistent with those presented here, challenge earlier assumptions of *MED13L* as a monogenic cause of complex congenital heart malformations, instead suggesting a broader phenotypic spectrum for *MED13L*-related disorders [23].

This expanded clinical understanding is further corroborated by Asadollahi, *et al.* (2017), who reported that only 3 of 23 individuals with *MED13L* mutations exhibited complex congenital heart anomalies [4].

Smol: Involvement of *MED13L* in the dTGA of these patients remains to be explained [12].

### Conclusion

This study provided valuable insights into the classification and implications of missense variants in the *MED13L* gene, based on data from the IVA 100k Genomes Project GRCh38 Germline Programme and GRCh37 Germline Programme - Rare Disease Programme. It emphasizes the importance of large-scale genomic initiatives in refining the classification of variants and improving diagnostic accuracy, ultimately enhancing patient care and management for individuals with *MED13L*-related and other genetic disorders.

In line with these findings, my case similarly demonstrates the value of considering multilocus contributions to complex phenotypes. Retrospective analysis suggests that the use of clinical genome sequencing was instrumental in moving beyond a linear diagnostic approach, allowing to recognize the contribution of more than one genetic disorder to the patient's overall presentation. This case exemplifies the capacity of clinical genome sequencing to elucidate blended phenotypes by uncovering multiple, co-occurring genetic etiologies [14].

Overall, the findings highlight the utility of CES in refining diagnoses, particularly in patients with atypical or complex clinical features. The ability to disentangle overlapping phenotypes through genomic analysis underscores the importance of broad, unbiased diagnostic tools in modern medical genetics.

The presence of multiple likely pathogenic variants in several probands also illustrated the complexity of genetic diagnoses and the need to consider the possibility of multiple concurrent conditions. This phenotypic overlap further supports the importance of accounting for both monogenic and polygenic contributions when interpreting genetic findings in individuals with neurodevelopmental disorders. However, larger cohorts are needed to confirm this observation. In sum, this study demonstrates how comprehensive genomic analyses can deepen our understanding of *MED13L* within broader neurodevelopmental risk architectures. It emphasizes the need for nuanced interpretation of genetic findings to support accurate diagnoses and optimized care strategies for affected individuals.

Finally, the case of patient 4 highlights the potential significance of intronic variants. The presence of a congenital heart defect in this patient raises the possibility that the intronic variant could act as a regulatory mutation impacting gene expression or splicing in a heart-specific context. If this transcript proves to be particularly active in the heart or during critical periods of cardiac development, its disruption could plausibly contribute to the observed cardiac phenotype. However, it is presented here for educational purposes to illustrate the complexities of variant annotation, including transcript versioning, database updates, and reinterpretation of legacy data over time (See figure 7). This particular case highlights the challenges of transcript-dependent variant annotation and underscores the evolving nature of genomic databases.

Clinically, this study represents the first focused analysis of VUS in *MED13L*. Despite the small cohort, results suggested that both VUS and pathogenic variants in *MED13L* can lead to a consistent and recognizable neurodevelopmental phenotype. The inclusion of only individuals with neurodevelopmental symptoms likely contributed to this phenotypic consistency, consistent with findings from previous studies, including those by Cafiero, *et al.* [8] and Haelst, *et al.* [13].

Importantly, this study observed a higher frequency of VUS among individuals of non-European descent, in line with data from ClinVar, the DDD study, and Chen, *et al.* [24]. This highlights a persistent challenge in genomic interpretation due to the underrepresentation of diverse populations in reference datasets. Improving the ethnic diversity of genomic databases remains critical for increasing diagnostic accuracy and uncovering population-specific variation.

From a diagnostic perspective, the study highlights the importance of variant reporting. For likely pathogenic variants identified, reporting to Genomics England via the Diagnostic Discovery Pathway remains a critical next step, enabling their return to NHS Genomic Laboratory Hubs (GLHs) for clinical evaluation and possible incorporation into patient management strategies [25]. Similarly, the three VUS identified in this study arose from probands where only duo sequencing had been conducted. This underscores the value of trio sequencing in enhancing variant classification accuracy, as classification often remains ambiguous in duo-sequenced cases. Nonetheless, practical limitations—such as patient or family preferences—may constrain the feasibility of parental sequencing in some instances. In line with updated ACGS guidelines, these VUS—supported by strong evidence—may be reclassified as likely pathogenic with additional data, such as trio sequencing, and therefore should also be reported to Genomics England [25-27].

### Further Research

The study's findings advocate for continued research and clinical focus on comprehensive genetic evaluations that leverage diverse, large-scale data for more inclusive and precise medical insights.

A complex relationship between *MED13L* mutations and cardiac phenotypes is suggested. In particular, the mechanisms and phenotypic consequences of intronic *MED13L* variants remain poorly understood. Additional data from *MED13L* carriers are necessary to refine the estimated penetrance of cardiac phenotypes.

Consistent with Chen, *et al.* [24], these findings underscore the importance of increasing ethnic diversity in genomic databases and improving methods to evaluate missense variants—especially those classified as VUS. Integrating clinical and experimental data, including functional studies, will be crucial for reducing uncertainty in variant interpretation.

Reclassification of VUS remains a challenge. Pathogenicity can often only be confirmed when similar cases are reported with matching phenotypes. Functional validation studies are essential to assess the impact of these variants.

This study also highlights the need for comprehensive genomic analysis to examine the role of *MED13L* within broader neurodevelopmental risk architectures. Deep phenotyping is necessary to better understand the clinical implications of such co-occurring mutations, and functional studies on the variants of uncertain significance found, should be carried out.

Intronic *MED13L* variants remain under-characterized. Muncke, *et al.* [5] identified a total of four missense and six intronic mutations in their cohort, noting that although intronic and synonymous variants cannot be categorically dismissed—particularly when absent from control populations—they did not undertake a detailed functional assessment of the intronic alterations. This gap in knowledge emphasizes the need for comprehensive studies that examine the contribution of non-coding variants to structural and anatomical abnormalities.

Future work should also explore age-related factors, cancer prevalence, and broaden the known phenotypic spectrum associated with *MED13L* variants.

### Funding Support

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### Ethics Declaration

This study used de-identified data from the Genomics England 100,000 Genomes Project. Ethical approval for the 100,000 Genomes Project was obtained by Genomics England, and all participants provided informed consent for research use of their data. No additional ethical approval was required for this secondary analysis. All analyses were conducted within the secure Genomics England Research Environment in accordance with data governance policies.

## Conflict of Interest

The author declares no competing interests.

## Data Availability

The data that support the findings of this study are available from Genomics England, but restrictions apply to the availability of these data, which were used under licence for the current study and are not publicly available. Access to the data can be obtained through application to Genomics England (<https://www.genomicsengland.co.uk/research/academic>).

## Bibliography

1. Deciphering Developmental Disorders Study. "Prevalence and architecture of *de novo* mutations in developmental disorders". *Nature* 542.7642 (2017): 433-438.
2. Sato S., *et al.* "A set of consensus mammalian mediator subunits identified by multidimensional protein identification technology". *Molecular Cell* 14.5 (2004): 685-691.
3. The Deciphering Developmental Disorders Study. "Large-scale discovery of novel genetic causes of developmental disorders". *Nature* 519.7542 (2015): 223-228.
4. Asadollahi R., *et al.* "Genotype-phenotype evaluation of *MED13L* defects in the light of a novel truncating and a recurrent missense mutation". *European Journal of Medical Genetics* 60.9 (2017): 451-464.
5. Muncke, N., *et al.* "Missense mutations and gene interruption in *PROSIT240*, a novel *TRAP240*-like gene, in patients with congenital heart defect (transposition of the great arteries)". *Circulation* 108.23 (2003): 2843-2850.
6. Najmabadi H., *et al.* "Deep sequencing reveals 50 novel genes for recessive cognitive disorders". *Nature* 478 (2011): 57-63.
7. Asadollahi R., *et al.* "Dosage changes of *MED13L* further delineate its role in congenital heart defects and intellectual disability". *European Journal of Human Genetics* 21.10 (2013): 1100-1104.
8. Cafiero C., *et al.* "Novel *de novo* heterozygous loss-of-function variants in *MED13L* and further delineation of the *MED13L* haploinsufficiency syndrome". *European Journal of Human Genetics* 23.11 (2015): 1499-1504.
9. Utami KH., *et al.* "Impaired development of neural-crest cell derived organs and intellectual disability caused by *MED13L* haploinsufficiency". *Human Mutation* 35.11 (2014): 1311-1320.
10. Genomics England. Personal Communication (2024).
11. Shamsani, J., *et al.* "A plugin for the Ensembl variant effect predictor that uses MaxEntScan to predict variant spliceogenicity". *Bioinformatics* 35.13 (2019): 2315-2317.
12. Smol T., *et al.* "*MED13L*-related intellectual disability: involvement of missense variants and delineation of the phenotype". *Neurogenetics* 19.2 (2018): 93-103.
13. Van Haelst MM., *et al.* "Further confirmation of the *MED13L* haploinsufficiency syndrome". *European Journal of Human Genetics* 23.1 (2015): 135-138.
14. Mullegama SV., *et al.* "Coupling clinical exome sequencing with functional characterization studies to diagnose a patient with familial Mediterranean fever and *MED 13L* haploinsufficiency syndromes". *Clinical Case Reports* 5.6 (2017): 833-840.

15. Maia N., *et al.* "Can the synergic contribution of multigenic variants explain the clinical and cellular phenotypes of a neurodevelopmental disorder?" *Genes* 13.1 (2021): 78.
16. Teles E Silva AL., *et al.* "Rare CACNA1H and RELN variants interact through mTORC1 pathway in oligogenic autism spectrum disorder". *Translational Psychiatry* 12.1 (2022): 234.
17. Wang T., *et al.* "Rare variants and the oligogenic architecture of autism". *Trends in Genetics* 38.9 (2022): 895-903.
18. # 615485 BAINBRIDGE-ROPER'S SYNDROME; BRPS.
19. A0A1W2PQS2 · A0A1W2PQS2\_HUMAN.
20. \*300522 IQ MOTIF- AND SEC7 DOMAIN-CONTAINING PROTEIN 2; IQSEC2.
21. Kalscheuer VM., *et al.* "Novel missense mutation A789V in IQSEC2 underlies X-linked intellectual disability in the MRX78 family". *Frontiers in Molecular Neuroscience* 8 (2016): 85.
22. Brea-Calvo G., *et al.* "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency". *American Journal of Human Genetics* 96.2 (2015): 309-317.
23. Adegbola A., *et al.* "Redefining the MED13L syndrome". *European Journal of Human Genetics* 23.10 (2015): 1308-1317.
24. Chen E., *et al.* "Rates and classification of variants of uncertain significance in hereditary disease genetic testing". *JAMA Network Open* 6.10 (2023): e2339571.
25. Genomics England: Public Data Browser. Self-defined Demographic information across all Genomics England Projects.
26. Genomics England - Public Data Browser. Types of rare diseases in the 100k Genomes rare disease group.
27. Genomics England - Public Data Browser. Overview of disorders of psychological development (F80-F89) in the 100k Genomes rare disease cohort.
28. Richards S., *et al.* "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology". *Genetics in Medicine* 17 (2015): 405-424.

**Volume 15 Issue 5 May 2026**

**©All rights reserved by Mairena Hirschberg.**